𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab study

✍ Scribed by Brad H. Rovin; Richard Furie; Kevin Latinis; R. John Looney; Fernando C. Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P. Garg; Paul Brunetta; Gerald Appel; LUNAR Investigator Group

Book ID
112002659
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
280 KB
Volume
64
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Histopathologic and clinical outcome of
Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis
✍ Iva Gunnarsson; Birgitta Sundelin; Thorunn JΓ³nsdΓ³ttir; Stefan H. Jacobson; Elisa πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 106 KB πŸ‘ 2 views

## Abstract ## Objective Rituximab is a monoclonal antibody directed against the CD20 marker of B cells. Because of its ability to deplete B lymphocytes, it has been suggested that the drug could be of benefit in B cell–dependent diseases, including systemic lupus erythematosus (SLE). The purpose